SCHEDULE 13G: Beryl Capital Management Discloses 9.8% Passive Stake in Inozyme Pharma
Beneficial Ownership Report
Beryl Capital Management and its affiliates have disclosed a passive beneficial ownership of 9.8% of Inozyme Pharma, Inc.'s common stock, totaling 6,321,584 shares.
Summary
- Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin have jointly filed a Schedule 13G, indicating beneficial ownership in Inozyme Pharma, Inc.
- The reporting group, led by Beryl Capital Management LLC and controlled by David A. Witkin, collectively holds 6,321,584 shares of Inozyme Pharma's Common Stock.
- This stake represents 9.8% of Inozyme Pharma's outstanding Common Stock, calculated based on 64,561,824 shares outstanding as of May 7, 2025.
- The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is moderately positive. While a Schedule 13G is a routine compliance filing, the disclosure of a significant 9.8% stake by an institutional investor can be viewed as a vote of confidence in the company, even if the investment is passive and not intended to influence control.
Positives
- The disclosure of a significant 9.8% stake by an institutional investor like Beryl Capital Management may signal confidence in Inozyme Pharma's long-term prospects, even if the investment is passive.
Future Outlook
The document does not contain any forward-looking statements or guidance regarding Inozyme Pharma's future operations or financial performance.
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an institutional investor in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership structure.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor perception and potentially the stock price, indicating institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| May 7, 2025 | Date on which 64,561,824 shares of Common Stock were outstanding, used for percentage calculation. |
| May 16, 2025 | Date of event which required the filing of this statement. |
| May 23, 2025 | Date of signing for the Schedule 13G filing and the Joint Filing Agreement. |
Keywords
Inozyme Pharma, Beryl Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Passive Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.